Definium TherapeuticsDFTX
Recorded

Definium Therapeutics 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration47 minParticipants22

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good afternoon, and welcome to the Definium Therapeutics Third Quarter 2026 Financial Results and Business Updates webcast. Currently, all participants are in a listen-only mode. This webcast is live on the Investor and Media section of Definium' website at definiumtx.com, and a replay will be available after the webcast. I would like to introduce Gita Jain, Head of Investor Relations at Definium. Please go ahead. Good afternoon.

Gita JainHead of Investor Relations

I am Gita Jain, Head of Investor Relations, and thank you for joining us today for Definium Therapeutics Third Quarter 2026 Financial Results and Recent Business Highlights conference call. All participants are in listen-only mode. This webcast is available live in the Investor section of Definium' website, and a replay will be available following the webcast. Leading the call today will be Rob Barrow, our Chief Executive Officer, joined by Dr. Dan Karlin, our Chief Medical Officer, Brandi Roberts, our Chief Financial Officer, and Matt Wiley, our Chief Commercial Officer. During today's call, we will make forward-looking statements, including statements regarding the potential safety, efficacy, and clinical and regulatory progress of our product candidates, the timing and potential scope of regulatory submissions, our commercial preparations, our anticipated cash runway, and our future expectations, plans, and prospects.

Gita JainHead of Investor Relations

These statements are subject to risks and uncertainties, including those described in our filings with the SEC and applicable Canadian securities regulators, including our annual report on Form 10-K and our Form 10-Q filed today. Forward-looking statements are based on management's assumptions, opinions, and estimates as of today, November 9, 2026. You are cautioned not to place undue reliance on these statements. Definium disclaims any obligation to update them, except as required by law. With that, I will turn the call over to Rob.

Rob BarrowCEO

Rob? Thank you, Gita, and thank you, everyone, for joining us today.

Rob BarrowCEO

The third quarter marked an important inflection point for Definium. With positive phase III results across three studies and two large psychiatric indications, we have moved beyond demonstrating the promise of DT120 ODT to establishing a compelling body of evidence that supports its potential to fundamentally change how anxiety and depression are treated. We believe these results position DT120 to become an important new treatment option for millions of people who continue to face significant unmet needs, and reinforce our conviction that we have an opportunity to help shape the future of psychiatric care. Just as important, we are making meaningful progress toward realizing that opportunity. DT120 has now received two FDA breakthrough therapy designations, reflecting the potential of this program to address serious conditions with substantial unmet need.

Rob BarrowCEO

Our engagement with FDA remains constructive, and we are advancing with urgency toward our planned NDA filing in the first half of 2027. We are focused not simply on reaching the next regulatory milestone, but on doing the work necessary to be ready to deliver DT120 to patients and healthcare providers if approved. That preparation extends across the organization. We are building the commercial capabilities, deepening our engagement with the medical community, and developing the scientific and educational foundation that will be important to introducing a fundamentally different treatment approach. We recognize that realizing the full potential of DT120 will require more than strong clinical data. It will require a thoughtful approach to regulatory execution, access, provider education, and ultimately, the patient experience. Those priorities are shaping how we are building Definium for its next chapter. At the same time, we are continuing to advance the pipeline with potential beyond DT120.

Rob BarrowCEO

Today, we shared initial results from our DT402 study in adults with autism spectrum disorder, which demonstrated encouraging signals across measures of socialization, communication, and functional outcomes. These findings support our continued investment in DT402 and underscore our ambition to build this company with multiple products with the potential to make a meaningful difference across therapeutic areas. We enter the next phase of our journey with strong clinical validation, growing regulatory momentum, and an organization increasingly positioned to translate innovation into impact. There is still important work ahead, and we believe Definium is well-positioned to pursue the opportunity in front of us and ultimately bring new treatment options to the people who need them. With that, I will turn the call over to Dan to provide more details on our clinical progress.

Dan KarlinChief Medical Officer

Thanks, Rob. We are pleased with the consistent DT120 clinical profile demonstrated in Emerge, Voyage, and Panorama. In each study, a single 100 microgram dose produced rapid and durable improvements in the disorders. Voyage enrolled 214 participants with moderate to severe GAD and met its primary endpoint and all key secondary efficacy endpoints. At week 12, DT120 showed a 5.4-point placebo-adjusted improvement on the Hamilton Anxiety Rating Scale, or HAM-A, with a P-value of less than 0.0001 and a Cohen's d effect size of 0.81. Improvement was evident as soon as day one at the first HAM-A assessment at week one and was maintained through week 12. Panorama demonstrated similar results in 245 participants. The 100 microgram dose led to a 5.1-point placebo-adjusted improvement on the HAM-A at week 12, with a P-value of less than 0.0001 and a Cohen's d of 0.64.

Dan KarlinChief Medical Officer

The study met its primary endpoint and all key secondary efficacy endpoints. The 50 microgram functional control further supported the interpretability of the efficacy and supported our selection of the 100 microgram dose. Our positive Emerge results announced in June provide strong support for the DT120 program in MDD. Emerge met its primary endpoint and all key secondary endpoints, demonstrating a rapid, clinically meaningful, and durable treatment effect following a single dose, with efficacy evident as early as day one and sustained through week 12. Based on these results, FDA granted breakthrough therapy designation to DT120 ODT for MDD, in addition to the previously granted breakthrough therapy designation for GAD. In the completed double-blind phases of all three studies, DT120 was generally well tolerated, with no drug-related serious adverse events and no suicidality signal. Most treatment-emergent adverse events occurred and resolved during the observed dosing session.

Dan KarlinChief Medical Officer

Treatment session dynamics were predictable and manageable. Participants completed the standardized end-of-session checklist in an average of about six hours consistently across the studies. Our fourth phase III study, and second in MDD, Ascend, continues to enroll well, with top-line data expected in 2027. We look forward to initiating Haven, our phase III study in post-traumatic stress disorder, or PTSD, in 2027. PTSD remains an area of significant unmet need, and we believe there is a compelling rationale to evaluate DT120 in PTSD based on the clinical profile we've observed in GAD and MDD. We plan to enroll approximately 200 participants, with change in a clinician-administered PTSD scale for DSM-5, or CAPS-5, at week eight as the primary endpoint.

Dan KarlinChief Medical Officer

As our DT120 clinical program advances, we are expanding our already substantial medical affairs team, including our field-based medical science liaisons, who engage with healthcare professionals to learn about and educate on the burden of disease, the emerging treatment landscape, and the growing body of evidence supporting DT120. Their work extends our clinical efforts as we prepare for regulatory submission, and ultimately helps ensure the medical community has a strong understanding of the data and DT120's potential role in treating anxiety and depression. Turning to DT402 for ASD. Our phase IIa study was a single-dose, open-label design to characterize DT402's pharmacodynamic and clinical effects, and to explore changes in measures of social behaviors and experiences, communication, and other functional outcomes. We were able to detect a sufficient signal to stop the study after enrolling five participants.

Dan KarlinChief Medical Officer

During treatment, several measures improved, including reduced rigidity and fixation, increased engagement in social settings, increased empathy and closeness to others, and reduced anxiety and irritability. DT402 was well tolerated, with the most common adverse events being euphoria, fatigue, and enhanced relaxation. This was a small, early-stage study, and the findings should be viewed in that context. Nonetheless, the consistent improvements across multiple measures are encouraging and support continued development. We plan to initiate a study in 2027 that will investigate the safety and clinical activity of multi-day dosing paradigms. ASD remains another area of substantial unmet need, particularly for therapies that can address core social perception and communication challenges. DT402 gives us an ongoing opportunity to develop our pipeline while remaining closely aligned with our scientific expertise and mission.

Dan KarlinChief Medical Officer

Taken together, the breadth and consistency of the DT120 data and the positive initial DT402 findings position Definium with both a potential near-term commercial product and a promising second asset. I'll now turn the call over to Matt.

Matt WileyChief Commercial Officer

Matt? Thanks, Dan. The strength and consistency of the DT120 data allows us to plan for launch with increasing clarity and sustained urgency.

Matt WileyChief Commercial Officer

We continue to advance the commercial infrastructure and capabilities needed to support DT120 if approved. Our focus is on translating that strong clinical profile into a launch model that works for patients, providers, and payers. We have advanced our market access strategy, distribution planning, patient services, commercial operations, and field deployment plans, while continuing to build the infrastructure needed to support the supervised treatment model. Provider and site readiness are critical to a successful launch. We are engaging the established and growing ecosystem of interventional psychiatry providers to assess capacity, workflow, and infrastructure needs, and to identify opportunities for additional support well ahead of launch. These insights are directly informing how we design our field organization, develop patient services, and equip providers to deliver DT120.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day